Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53

Fatah Kashanchi, John Araujo, Jay Doniger, Sumitra Muralidhar, Renee Hoch, Samir Khleif, Elliot Mendelson, Jerry Thompson, Norio Azumi, John N. Brady, Mario Luppi, Giuseppe Torelli, Leonard J. Rosenthal

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication. In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.

Original languageEnglish (US)
Pages (from-to)359-367
Number of pages9
JournalOncogene
Volume14
Issue number3
DOIs
StatePublished - Jan 1 1997

Fingerprint

Human Herpesvirus 6
Open Reading Frames
Genes
Proteins
Oncogenes
HIV-1
Neoplasms
Immunoblastic Lymphadenopathy
HIV Long Terminal Repeat
Tumor Suppressor Protein p53
Fibrosarcoma

Keywords

  • HHV-6 transformation gene
  • p53 binding
  • p53-activated transcription

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Kashanchi, F., Araujo, J., Doniger, J., Muralidhar, S., Hoch, R., Khleif, S., ... Rosenthal, L. J. (1997). Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene, 14(3), 359-367. https://doi.org/10.1038/sj.onc.1200840

Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. / Kashanchi, Fatah; Araujo, John; Doniger, Jay; Muralidhar, Sumitra; Hoch, Renee; Khleif, Samir; Mendelson, Elliot; Thompson, Jerry; Azumi, Norio; Brady, John N.; Luppi, Mario; Torelli, Giuseppe; Rosenthal, Leonard J.

In: Oncogene, Vol. 14, No. 3, 01.01.1997, p. 359-367.

Research output: Contribution to journalArticle

Kashanchi, F, Araujo, J, Doniger, J, Muralidhar, S, Hoch, R, Khleif, S, Mendelson, E, Thompson, J, Azumi, N, Brady, JN, Luppi, M, Torelli, G & Rosenthal, LJ 1997, 'Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53', Oncogene, vol. 14, no. 3, pp. 359-367. https://doi.org/10.1038/sj.onc.1200840
Kashanchi, Fatah ; Araujo, John ; Doniger, Jay ; Muralidhar, Sumitra ; Hoch, Renee ; Khleif, Samir ; Mendelson, Elliot ; Thompson, Jerry ; Azumi, Norio ; Brady, John N. ; Luppi, Mario ; Torelli, Giuseppe ; Rosenthal, Leonard J. / Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. In: Oncogene. 1997 ; Vol. 14, No. 3. pp. 359-367.
@article{ceb12a2de9d34947a13e6b3c28a30a32,
title = "Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53",
abstract = "The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication. In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.",
keywords = "HHV-6 transformation gene, p53 binding, p53-activated transcription",
author = "Fatah Kashanchi and John Araujo and Jay Doniger and Sumitra Muralidhar and Renee Hoch and Samir Khleif and Elliot Mendelson and Jerry Thompson and Norio Azumi and Brady, {John N.} and Mario Luppi and Giuseppe Torelli and Rosenthal, {Leonard J.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/sj.onc.1200840",
language = "English (US)",
volume = "14",
pages = "359--367",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53

AU - Kashanchi, Fatah

AU - Araujo, John

AU - Doniger, Jay

AU - Muralidhar, Sumitra

AU - Hoch, Renee

AU - Khleif, Samir

AU - Mendelson, Elliot

AU - Thompson, Jerry

AU - Azumi, Norio

AU - Brady, John N.

AU - Luppi, Mario

AU - Torelli, Giuseppe

AU - Rosenthal, Leonard J.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication. In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.

AB - The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication. In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.

KW - HHV-6 transformation gene

KW - p53 binding

KW - p53-activated transcription

UR - http://www.scopus.com/inward/record.url?scp=8044248407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8044248407&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1200840

DO - 10.1038/sj.onc.1200840

M3 - Article

C2 - 9018122

AN - SCOPUS:8044248407

VL - 14

SP - 359

EP - 367

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 3

ER -